Abstract
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia in adult population and confers significant thromboembolic risk. Endothelial dysfunction has been recognized as a possible contributor to thrombogenesis in AF. The arrhythmia has been associated with thrombogenic atrial endocardial lesions and evidence of increased circulating biomarkers of endothelial dysfunction (e.g. von Willebrand factor, soluble thrombomodulin, E-selectin, asymmetric dimethylarginine, circulating endothelial cells and microparticles), and impairment of endothelium-dependent vasodilatation in the peripheral and coronary circulation has been reported in AF patients. Increased levels of biomarkers of endothelial origin (e.g. von Willebrand factor, soluble thrombomodulin, E-selectin, asymmetric dimethylarginine) have been associated with adverse outcomes in AF patients. Importantly, endothelial dysfunction has been documented in AF patients without cardio-pulmonary comorbidities or risk factors (so-called ‘lone AF’), as well.
In this review, we provide an overview of contemporary evidence for the alterations in endothelial function and endothelial injury in AF, with a focus on endothelial (dys)function in lone AF.
Keywords: Lone atrial fibrillation, endothelial dysfunction, endothelial damage, endocardial dysfunction, von Willebrand factor, thrombomodulin, E-selectin, asymmetric dimethylarginine, circulating endothelial cells, progenitor endothelial cells, microparticles, endotheliumdependent vasodilatation, flow-mediated dilation.
Current Pharmaceutical Design
Title:Endothelial (Dys)Function in Lone Atrial Fibrillation
Volume: 21 Issue: 5
Author(s): Marija M. Polovina, Gregory Y.H. Lip and Tatjana S. Potpara
Affiliation:
Keywords: Lone atrial fibrillation, endothelial dysfunction, endothelial damage, endocardial dysfunction, von Willebrand factor, thrombomodulin, E-selectin, asymmetric dimethylarginine, circulating endothelial cells, progenitor endothelial cells, microparticles, endotheliumdependent vasodilatation, flow-mediated dilation.
Abstract: Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia in adult population and confers significant thromboembolic risk. Endothelial dysfunction has been recognized as a possible contributor to thrombogenesis in AF. The arrhythmia has been associated with thrombogenic atrial endocardial lesions and evidence of increased circulating biomarkers of endothelial dysfunction (e.g. von Willebrand factor, soluble thrombomodulin, E-selectin, asymmetric dimethylarginine, circulating endothelial cells and microparticles), and impairment of endothelium-dependent vasodilatation in the peripheral and coronary circulation has been reported in AF patients. Increased levels of biomarkers of endothelial origin (e.g. von Willebrand factor, soluble thrombomodulin, E-selectin, asymmetric dimethylarginine) have been associated with adverse outcomes in AF patients. Importantly, endothelial dysfunction has been documented in AF patients without cardio-pulmonary comorbidities or risk factors (so-called ‘lone AF’), as well.
In this review, we provide an overview of contemporary evidence for the alterations in endothelial function and endothelial injury in AF, with a focus on endothelial (dys)function in lone AF.
Export Options
About this article
Cite this article as:
M. Polovina Marija, Y.H. Lip Gregory and S. Potpara Tatjana, Endothelial (Dys)Function in Lone Atrial Fibrillation, Current Pharmaceutical Design 2015; 21 (5) . https://dx.doi.org/10.2174/1381612820666140825143028
DOI https://dx.doi.org/10.2174/1381612820666140825143028 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology Biomarkers in Acute Heart Failure Syndromes: An Update
Current Cardiology Reviews The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) The Hellp Syndrome: A Review
Current Women`s Health Reviews Cardiovascular Effects of Glucagon-Like Peptide 1
Mini-Reviews in Medicinal Chemistry Sudden Unexplained Death in Infancy and Long QT Syndrome
Current Pediatric Reviews Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Ablation of Complex Fractionated Atrial Electrograms in Catheter Ablation for AF; Where have we been and where are we going?
Current Cardiology Reviews Models and Methods in Cardiac Imaging for Metabolism Studies
Current Pharmaceutical Design Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Imaging of Visceral Adipose Tissue: An Emerging Diagnostic Tool and Therapeutic Target
Current Drug Targets - Cardiovascular & Hematological Disorders Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Genomic Databases and the Search of Protein Targets for Protozoan Parasites
Current Drug Targets